BioCity Nottingham appoints directors
This article was originally published in Scrip
The UK bioscience incubator BioCity Nottingham has appointed Lucy Marcus and Stefan Ogrodzinski to its board of directors. Ms Marcus is the founder and CEO of Marcus Venture Consulting, while Mr Ogrodzinski is a life sciences entrepreneur, having been a founding director of BioStatus, BioSuspensions, nanoTherices and magneCell.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.